Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects

General Physiology and Biophysics

Volumn 22, Issue 1, 2003, Pages 103-113

  Žourková, Alexandra ^a   Hadasova E ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Adverse effects; CYP 2D6; Depression; Paroxetine; Phenotype

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMAZEPAM; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; FLUOXETINE; NEUROLEPTIC AGENT; OXAZEPAM; PAROXETINE; PHENOTHIAZINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ACCOMMODATION; ADULT; AKATHISIA; ANAMNESIS; ANORGASMIA; ARTICLE; AUTONOMIC NEUROPATHY; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DREAMING; DRUG ERUPTION; DRUG METABOLISM; DRUG TOLERABILITY; EJACULATION DISORDER; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; EYE DISEASE; FATIGUE; FEMALE; FEMALE SEXUAL DYSFUNCTION; GENE CONVERSION; GENETIC PROCEDURES; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; LIBIDO DISORDER; LONG TERM CARE; MALE; MENTAL CONCENTRATION; MICTURITION DISORDER; NAUSEA; PARESTHESIA; PATIENT CODING; PHENOTYPE; POLYDIPSIA; POLYURIA; SEXUAL DYSFUNCTION; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SWEATING; TACHYCARDIA; TENSION; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; DEPRESSION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PHENOTYPE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 0037865865     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Alván G., Bechtel P., Iselius L., Gundert-Remy U. (1990): Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39, 533-537
2. Brosen K., Hansen J. G., Nielsen K. K., Sindrup S. H., Gram L. F. (1993): Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur. J. Clin. Pharmacol. 44, 349-355
3. Daly A. K., Brockmöller J., Broly F., Eichelbaum M., Evans W. E., Gonzales F. J., Huang J. D., Idle J. R., Ingelman-Sundberg M., Ishizaki T., Jacqz-Aigrain E., Meyer U. A., Nebert D. W., Steen V. M., Wolf C. R., Zanger U. M. (1996): Nomenclature for human CYP 2D6 alleles. Pharmacogenetics 6, 193-201
4. de Leon J., Barnhill J., Rogers T., Boyle J., Chou W. H., Wedlund P. J. (1998): Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am. J. Psychiatry 155, 1278-1280
5. Ereshefsky L. (1996): Drug-drug interaction involving antidepressants: Focus on venlafaxine. J. Clin. Psychopharmacol. 16, (Suppl. 2) S37-53
6. Edwards J. G., Anderson I. (1999): Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57, 507-533
7. Hadašová E., Franke G., Zschiesche M., Češková E., Zelenková O., Siegmund W. (1996 : Debrisoquine 4-hydroxylation and sulphamethazine N-acetylation in patients with schizophrenia and major depression. Br. J. Clin. Pharmacol. 41, 428-431
8. Hamilton M. (1997): Hamilton Psychiatric Rating Scale for Depression. In: Praktický manuál psychiatrických posuzovacích stupnic (Ed. V. Filip, Czech translation), Zprávy 130, pp. 99-102, PCP Praha
9. Heim M., Meyer U. A. (1990): Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336, 529-532
10. Kalow W., Tyndale R. F. (1992): Debrisoquine/sparteine monooxygenase and other P450s in brain. In: Pharmacogenetics of Drug Metabolism. (Ed. Kalow W.), pp. 649-656, Pergamon Press, New York
11. Kaye C. M., Haddock R. E., Langley P. F., Mellows G., Tasker T. C., Zussman B. D., Greb W. H. (1989): A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand. 80 (Suppl.), 60-75
12. Kohler D., Hartter S., Fuchs K., Sieghart W., Hiemke C. (1997): CYP 2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 7, 453-461
13. Lingjaerde O., Ahlfors U. G., Bech P., Dencker S. J., Elgen K. (1987): The UKU side effects rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 334, (Suppl.) 1-100
14. Llerena A., Edman G., Cobaleda J., Benitez J., Schalling D., Bertilsson L. (1993): Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 87, 23-28
15. Maréz D., Legrand M., Sabbagh N., Guidice J. M., Spire C., Laffite J. J., Meyer U. A., Broly F. (1997): Polymorphism of the cytochrome P450 CYP2D6 gene in European population: characterisation of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7, 193-202
16. Niznik H. B., Tyndale R. F., Sallee F. R., Gonzales F. J., Hardwick J. P., Inaba T., Kalow W. (1990): The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H} GBR-12935 binding proteins. Arch. Biochem. Biophys. 276, 424-432
17. Park Y. H., Kullberg M. P., Hinsvark O. N. (1984): Quantitative determination of dextromethorphan and three metabolites in urine by reversed-phase high performance liquid chromatography. J. Pharm. Sci. 73, 24-29
18. Preskorn S. H., Magnus R. D. (1994): Inhibition of hepatic P450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol. Bull. 30, 251-259
19. Saxena R., Shaw G. L., Reiling M. V., Frame J. N., Moir D. T., Evans W. E., Caporaso N., Weiffenbach B. (1994): Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum. Mol. Genet. 3, 923-926
20. Segraves R. T. (1989): Effects of psychotropic drugs on human erection and ejaculation. Arch. Gen. Psychiatry 46, 275-284
21. Sindrup S. H., Brosen K., Gram L. F., Hallas J., Skjelbo E., Allen A., Allen G. D., Cooper S. M., Mellows G., Tasker T. C. et al. (1992): The relationship between paroxetine and the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 51, 278-287
22. Spina E., Gitto C., Avenoso A., Campo G. M., Caputi A. P., Perucca E. (1997): Relationship between plasma desipramine levels, CYP 2D6 phenotype and clinical response to desipramine: a prospective study. Eur. J. Pharmacol. 51, 395-398
23. Vandel S., Bertschy G., Bonin B., Nezelof S., Francois T. H., Vandel B., Sechter D., Bizouard P. (1992): Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology (Engl. Transl.) 25, 202-207
24. Zelenková O., Fuchs K., Kasper S., Kapitany T., Hadašová E., Češková E. (1997): Metabolic polymorphism of CYP2D6 in patients treated with neuroleptics - a phenotypic versus genotypic study. Homeostasis Health. Dis. 38, 10-12